Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

Homerbedloe, That was an interesting read, but

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36566
(Total Views: 338)
Posted On: 03/24/2021 10:58:29 AM
Posted By: Assiduous
Re: homerbedloe #27796
Homerbedloe,

That was an interesting read, but too much lawyerese. Over a year ago, NuGenerex was spun out from Generex, assigned the NGIO ticker symbol and is a completely independent corporation with a board of directors. See SEC filings https://www.sec.gov/cgi-bin/browse-edgar?acti...p;count=40

At that time it was and still is a privately held company with about (as you said) 65% owned by Generex (GNBT) and 35% owned by individuals rewarded with free dividend shares. The goal is to make NGIO a publicly traded company. Even though there are many people owning the 35% of NGIO, these share were awarded privately as a dividend to GNBT shareholders and not to the general public, thus still keeping NGIO a privately held company.

To make NuGenerex a publicly traded company, it must be listed on a stock exchange (NASDAQ) meeting all their requirements, be SEC compliment (done), and have shares being offered to the public so anyone (not just dividend holders) can own them. This is what the IPO will accomplish when NGIO issues/sell some of their treasury stock.

As for GNBT getting its reward, let’s say the NGIO IPO goes at $5/share, GNBT will instantly gain about $320,000,000 worth of liquidly with the NGIO shares it owns and can sell anytime for any reason and use for any purpose. NGIO will be infused with IPO cash. And GNBT shareholders will be rewarded with the GNBT pps increase, should be around $3/share. To put it bluntly, there is no way in hell that if GNBT has $320 million in cash with only 114 million outstanding shares, that the pps can still be in the $.30s/$.40s.


(5)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us